Search for content, post, videos

Oncopeptides announces new data

Klaas Bakker

Oncopeptides has announced that data from the phase 2 study HORIZON, and additional clinical and preclinical data that further evaluate the therapeutic peptide-drug conjugate platform, have been accepted by the European Hematology Association (EHA).

“The primary read-out of the HORIZON-data represents an important milestone for Oncopeptides. They lay the ground for the New Drug Application to the FDA, seeking accelerated approval for intravenous melflufen in combination with dexamethasone,” says Klaas Bakker, CMO of Oncopeptides. “Melflufen could provide a novel treatment option with a unique mechanism of action for a group of myeloma patients with a particularly poor prognosis.”

Melflufen (melphalan flufenamide) is an anticancer peptide-drug conjugate that delivers an alkylating payload into tumor cells. Melflufen is in late stage clinical development for a potential treatment of patients with relapsed refractory multiple myeloma (RRMM).

The full EHA abstract book can be found on

Photo of Klaas Bakker, CMO of Oncopeptides